Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate — two of the nine herbs have large randomized literatures; the rest are thinner, and the dosing is the open question
What NeuroPrime Claims To Be
NeuroPrime is a liquid brain-support formula taken as a single drop per day, marketed for focus, memory and general cognitive sharpness. It sits in the “nootropic botanical stack” category — a handful of traditional herbs plus a couple of algae, bundled under the promise of clearer thinking.
The category has a mixed reputation, and deservedly so. But the specific herbs here are not obscure. Two of them are among the most heavily trialed plant cognitive agents in the world.
What’s Actually In It
Nine ingredients are named:
- Bacopa monnieri (brahmi)
- Ginkgo biloba
- Lion’s mane (Hericium erinaceus)
- Pine bark extract
- Moringa
- Tamarind
- Chlorella
- Spirulina
- Neem
No milligram amounts are published for any of them. That matters more here than it does for most products, and the reason is in the research below.
What The Research Shows
According to PubMed, the evidence clusters heavily around Bacopa and Ginkgo, with lion’s mane a distant and much more preliminary third.
Bacopa has the strongest signal of the nine — but only at real doses. A 2026 network meta-analysis pooled 29 randomized controlled trials in 2,107 healthy adults comparing Bacopa and Ginkgo head to head. High-dose Bacopa (≥600 mg/day) significantly outperformed placebo on working memory and short-term memory, and ranked first out of every arm tested. Low-dose Bacopa (300 to under 600 mg/day) did not beat placebo on working memory. That dose threshold is the single most useful number in this whole review. DOI
Ginkgo underperformed Bacopa in that same analysis. Neither high-dose (≥240 mg/day) nor low-dose Ginkgo separated from placebo on working memory. Ginkgo’s better showing is in clinical rather than healthy populations — a meta-analysis of 18 randomized trials in 1,642 people with Alzheimer’s disease found that Ginkgo preparations added to donepezil improved Mini-Mental State Examination and daily-living scores over donepezil alone, though the authors flagged the underlying trials as methodologically poor. DOI
And a broader look at herbal nootropics is sobering. An umbrella review of 37 systematic reviews covering 13 herbal medicines for dementia and cognitive function found that only about 46% of the 90 pooled outcomes reached statistical significance, 65% of the reviews were rated critically low quality, and Ginkgo specifically was supported only by “weak” evidence. Just three of the 13 herbs cleared the bar for “suggestive” evidence. DOI
Lion’s mane is genuinely early-stage. A double-blind pilot in 41 healthy adults aged 18–45 found that a single 1.8 g dose produced faster Stroop task performance at 60 minutes, and that 28 days of supplementation produced a non-significant trend toward reduced subjective stress (p = 0.051). The authors were explicit that the sample was small and that null and negative findings also appeared. DOI A separate crossover trial found 1 g of Nordic-grown lion’s mane improved working memory and reaction time two hours after ingestion. DOI
Pine bark extract has mechanistic and some human support. A review of Pycnogenol — the standardized French maritime pine bark extract — found multimodal antioxidant activity in lab and animal work, with several human studies reporting improved cognitive function after chronic administration. This is real but it is a narrative review, not a pooled analysis of randomized trials. DOI
Moringa, tamarind, chlorella, spirulina and neem did not turn up randomized cognitive evidence in this search. They are food-grade plants with nutritional value; treat them as filler for cognitive purposes until someone trials them.
The Honest Verdict
What holds up: Bacopa monnieri is a legitimately evidence-backed cognitive ingredient, and it is the best thing in this formula. Ginkgo has an enormous literature and a plausible role as an adjunct in clinical populations. Lion’s mane has early randomized signals worth watching. Pine bark has coherent mechanism plus some human data.
What doesn’t: The dose problem is unavoidable. The Bacopa evidence lives at 600 mg/day and above; below that threshold, the network meta-analysis found no working-memory benefit versus placebo. A single daily drop is not a plausible delivery vehicle for 600 mg of anything. Without published per-ingredient amounts there is no way to check whether this formula lands anywhere near the doses that produced the results above — and that is the question to put to the seller before buying. Ginkgo’s own evidence base was rated weak by an umbrella review, and five of the nine ingredients have no cognitive trial evidence at all.
Who this makes sense for: Someone curious about botanical nootropics who understands they are buying a low-cost, low-risk experiment rather than a studied intervention, and who will ask for the label breakdown first.
Who should skip it: Anyone taking anticoagulants or antiplatelet medication (Ginkgo is a known interaction), anyone hoping to address diagnosed memory loss, and anyone who wants the Bacopa evidence specifically — in that case a standardized Bacopa extract at 600 mg/day or more is the dose that actually beat placebo.
Check current pricing and availability
View NeuroPrime on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your dentist or physician before starting any supplement, especially if you have a diagnosed condition or take medication.
Research cited via PubMed:
- Tiemtad P, et al. Phytomedicine. 2026;153:157915. DOI
- Li D, et al. Front Aging Neurosci. 2023;15:1124710. DOI
- Sawangjit R, et al. Phytother Res. 2023;37(6):2364-2380. DOI
- Docherty S, et al. Nutrients. 2023;15(22):4842. DOI
- La Monica MB, et al. Nutrients. 2023;15(24):5018. DOI
- Simpson T, et al. Front Pharmacol. 2019;10:694. DOI